## ADMA: ADMA Biologics, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -4.7% below STRENGTH zone (3.0-6.0%); PEG 1.34 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.7% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($16.71)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 2
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. ADMA Biologics to Present at the J.P. Morgan Healthcare Conference on January 12, 2026**
- Source: The Manila Times | 20260105T120908 | Somewhat-Bullish | Relevance: 100%
- ADMA Biologics will participate in a podium presentation at the J.P. Morgan Healthcare Conference on January 12, 2026, where Adam Grossman, President and CEO, will present. The presentation will be available via live audio webcast on the company's investor relations website. ADMA Biologics is a biopharmaceutical company specializing in plasma-derived biologics for immunodeficient patients.

**2. Why (ADMA) Price Action Is Critical for Tactical Trading**
- Source: Stock Traders Daily | 20260104T201200 | Somewhat-Bearish | Relevance: 100%
- This article analyzes Adma Biologics Inc (NASDAQ: ADMA) price action, indicating weak near and mid-term sentiment but a neutral long-term outlook. It highlights an exceptional 60.6:1 risk-reward setup targeting a 17.6% gain against 0.3% risk. The piece also outlines three distinct AI-generated trading strategies with specific entry, target, and stop-loss levels for different risk profiles.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.08M) |
| Sells | 2 ($0.24M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 49.5% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Blackrock Inc.: 15.0% (-2.3%)
- Vanguard Group Inc: 8.8% (-1.8%)
- State Street Corpora: 5.7% (+12.3%)
- Invesco Ltd.: 5.2% (-2.4%)
- Sachem Head Capital : 3.8% (+100.0%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-2.7% 5d) with bearish MACD, trend may be turning.
2. Elevated short interest (9.7%): bears positioning against stock.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.34 suggests fair value with growth premium. Forward P/E 19.2x attractive for 57% earnings growth. Quality metrics strong (ROE 63%, ROA 22%, margin 43%). Balance sheet: strong liquidity (7.1x), low leverage (D/E 0.32). Revenue growth strong at 24% YoY. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $4.3B |
| Beta | 0.46 |
| 52W Range | $13.50 - $25.67 |
| Short Interest | 9.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.34 |
| Forward P/E | 19.2 |
| Current P/E | 30.1 |
| YoY Growth | 56.7% |
| EPS Direction | RISING |

### Technicals

MRS_10 deteriorating from -2.0% to -4.7% (-2.7% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 7.7pp (needs >3.0% for momentum thesis). Underperforming sector by 5.2pp, stock-specific weakness. Below SMA200 (0.99x), long-term trend not supportive. RSI neutral at 43. OFD pattern: +SLN (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -4.66% (CS: 3) | Weak |
| RSI_14 | 43.2 | Neutral |
| MACD Histogram | -0.32 | Bearish |
| vs SMA20 | 0.936x | Below |
| vs SMA50 | 1.024x | Above |
| vs SMA200 | 0.992x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $18.03
- **Stop Loss:** $16.71 (7.3% risk)
- **Target:** $19.35 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 653
- **Position Value:** $11,773.59
- **Portfolio %:** 11.77%
- **Risk Dollars:** $862.50
- **Risk Per Trade:** 0.86%
- **Modifiers:** L1 115% | L2 75% | Combined 0.86x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

*NORMAL regime with moderate risk appetite. VIX remains calm at 14.9 (8th percentile) with positive yield curve (+65bps) and healthy breadth (59.2%), though elevated put/call ratio (1.27) suggests institutional hedging despite surface calm. Focus on quality with awareness of hedging activity divergence.*

### Earnings

**Next:** 2026-03-02 (Est: $0.20)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.15 | $0.16 | +2.6% |
| 2025Q2 | $0.14 | $0.14 | +7.4% |
| 2025Q1 | $0.17 | $0.11 | -33.3% |
| 2024Q4 | $0.15 | $0.14 | -9.3% |

---
*RULE-based L3 | 2026-01-07 09:35 | MRS_10*